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Although epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) are a key therapy used
for patients with EGFR-mutant non-small cell lung cancer (NSCLC), some of whom do not respond well to
its therapy. Cytokine including IL-6 secreted by tumour cells is postulated as a potential mechanism for
the primary resistance or low sensitivity to EGFR-TKIs. Fifty-two patients with advanced EGFR-mutant
NSCLC who had received geﬁtinib were assessed retrospectively. The protein expression of IL-6 in the
tumour cells was assessed by immunostaining and judged as positive if  50 of 100 tumour cells stained
positively. Of the 52 patients, 24 (46%) and 28 (54%) were deﬁned as IL-6-postitive (group P) and IL-6-
negative (group N), respectively. Group P had worse progression-free survival (PFS) than that of group
N, which was retained in the multivariate analysis (hazard ratio: 2.39; 95 %CI: 1.00e5.68; p < 0.05). By
contrast, the PFS after platinum-based chemotherapy did not differ between groups P and N (p ¼ 0.47). In
cell line-based model, the impact of IL-6 on the effect of EGFR-TKIs was assessed. The combination of
EGFR-TKI and anti-IL-6 antibody moderately improved the sensitivity of EGFR-TKI in lung cancer cell
with EGFR mutation. Interestingly, suppression of EGFR with EGFR-TKI accelerated the activation of
STAT3 induced by IL-6. Taken together, tumour IL-6 levels might indicate a subpopulation of EGFR-
mutant NSCLC that beneﬁts less from geﬁtinib monotherapy.
© 2017 Elsevier Inc. All rights reserved.1. Introduction
Following the discovery of epidermal growth factor receptor
(EGFR) mutations in non-small cell lung cancer (NSCLC), ﬁrst-
generation EGFR-tyrosine kinase inhibitor (EGFR-TKI) (geﬁtinib or
erlotinib) therapy was shown to yield better progression-free sur-
vival (PFS) (medians: 10.8e5.7 vs. 5.8e5.2 months, respectively)
and comparable overall survival (OS) (medians: 30.5e21.6 vs.ical Medicine, Okayama Uni-
, 700-8558, Japan.
).23.6e21.9months, respectively), comparedwith standard cytotoxic
chemotherapy, in chemo-naïve patients with EGFR-mutant tu-
mours. Furthermore, afatinib, a 2nd-generation EGFR-TKI, yielded a
better OS (median: 27.3 vs. 24.3 months, respectively; p ¼ 0.037)
and PFS (median: 11.1 vs. 6.9, respectively; p ¼ 0.001) than those
using standard cytotoxic chemotherapy [1e8]. These results sug-
gest that EGFR-TKIs are key agents in EGFR-mutant tumours;
however, resistance to this promising agent is inevitably encoun-
tered during its therapy [9,10], suggesting the limited efﬁcacy of
EGFR-TKIs.
Overexpression of interleukin (IL)-6 in tumour cells is postu-
lated to be a potential mechanism for such primary resistance or
low sensitivity to EGFR-TKI in preclinical models [11,12]; an
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growth factor (TGF)-beta signaling weakened sensitivity to EGFR-
TKIs in EGFR-mutated NSCLC cells [11]. Furthermore, reduction of
the tumour IL-6 level by an IL-6-neutralizing antibody combined
with EGFR-TKI successfully led to the tumour growth inhibition in
EGFR-mutated, IL-6 overexpressing NSCLC cells resistant to EGFR-
TKI monotherapy. Other researchers reported that mutant EGFR
could activate the gp130/JAK/STAT3 pathway by means of IL-6
upregulation in primary human lung adenocarcinoma cells [12].
To date, the role of IL-6 in the sensitivity to EGFR-TKIs in EGFR-
mutant NSCLC has not yet been fully assessed clinically. Based on
preclinical study results, we evaluated here, using clinical speci-
mens, whether the tumor IL-6 level can affect the effect of EGFR-TKI
therapy in NSCLC patients with EGFR-mutant tumours.
2. Methods
2.1. Patients and treatments
We retrospectively assessed patients registered in the database
during the study period, from 2005 to 2013, at our hospital. The
patients included in the study were those who 1) had locally
advanced, metastatic or postoperative recurrent NSCLC, 2) had
EGFR-mutant tumours, 3) were deemed unﬁt for curative surgery
and irradiation, 4) underwent geﬁtinib monotherapy (250 mg/
body/day, orally), irrespective of the line of treatment, 5) had no
prior EGFR-TKI therapy, and 6) had tumour samples (formalin-
ﬁxed, parafﬁn-embedded [FFPE]) that were sufﬁcient for IL-6 im-
munostaining. The tumour EGFR mutation status was assessed by
direct sequencing or the polymerase chain reaction (PCR) clamp
method, as described previously [9,10]. This study was approved by
the institutional review board of Okayama University (No. 1506-
002).
2.2. Data abstraction
The following information regarding the patients was retro-
spectively extracted frommedical charts: age, gender, performance
status (PS), disease stage, smoking status, tumour histology, and
type of EGFR mutations. For this study, we basically assessed the
tumour response every 2 or 3 months in each patient according to
the Response Evaluation Criteria in Solid Tumours (RECIST) version
1.1. The diagnosis of brain metastasis was based on magnetic
resonance imaging or computed tomography.
2.3. Immunostaining of IL-6 in tumour and serum samples
Serial 4-mm-thick sections were sliced from FFPE tissue blocks
and subjected to haematoxylin and eosin staining and immuno-
histochemistry. We stained each tumour specimen with the anti-
human IL-6 antibody (mouse monoclonal antibody; Leica Bio-
systems, Newcastle UponTyne, UK; product code: NCL-L-IL6), using
the Leica BOND-MAX automated immunostainer (Leica Micro-
systems, Wetzlar, Germany) [13,14]. This antibody was applied at a
1:200 dilution for 15 min at room temperature. Sections were
scored independently by two physicians (YK and TT) and one
pathologist (TT), without any information about the clinical course
and outcome of the patients; the intensity of staining was scored
negative or positive if the proportion of stained cells was 0e50% or
51-100% out of 100 cells, referring to prior relevant criteria [15]. We
deﬁned group P as those with IL-6-positive tumours and group N as
those with IL-6-negative tumours.
Peripheral blood samples, collected from 11 (21%) of the 52
patients before receiving geﬁtinib treatment, were stored at80 C
until use. The serum IL-6 level was measured by chemiluminescentenzyme immunoassay (CLEIA) using the Quanti Glo Human IL-6
Immunoassay 2nd Generation kit (R&D Systems, Inc., Minneap-
olis, MN, USA).
2.4. IL-6 expression and sensitivity to geﬁtinib and/or anti-IL-6
antibody in preclinical models
To check the expression levels of IL-6 protein in 10 EGFR-mutant
NSCLC cell lines [16,17], the supernatant IL-6 levels in the cell cul-
ture were measured by the enzyme-linked immunosorbent assay
(ELISA), using Human IL-6 Quantikine ELISA Kit D6050 (R&D Sys-
tems, MN, USA). Sensitivities of each NSCLC cell to geﬁtinib and
anti-IL-6 antibody (Biolegend, CA, USA) were evaluated by MTT
assay.
2.5. Immunoblotting analysis
Cells and frozen tissue were lysed in a radio-
immunoprecipitation assay buffer [1% Triton X-100, 0.1% SDS,
50 mmol/L Tris-HCl (pH 7.4), 150 mmol/L NaCl, 1 mmol/L EDTA,
1 mmol/L EGTA, 10 mmol/L b-glycerolphosphate, 10 mmol/L NaF,
1 mmol/L sodium orthovanadate-containing protease inhibitor
tablets (Roche Applied Sciences GmbH, Mannheim, Germany)].
Proteins were separated by electrophoresis on polyacrylamide gels,
transferred onto nitrocellulose membranes, and probed with spe-
ciﬁc antibodies followed by detection with Enhanced Chem-
iluminescence Plus (GE Healthcare Biosciences, Piscataway, NJ,
USA).
2.6. Statistical analyses
We primarily assessed the causal relationship between the
tumour IL-6 expression level and therapeutic efﬁcacy, particularly
progression-free survival (PFS). Differences between groups were
assessed using the chi-squared test. PFS was deﬁned as the duration
from the date of initiation of EGFR-TKI treatment or cytotoxic
chemotherapy to the date of documented relapse. OS was deﬁned
as the duration from the date of initiation of EGFR-TKI treatment to
the date of death. PFS and OS curves were constructed using the
KaplaneMeier product-limit method. Differences between
KaplaneMeier curves were evaluated by the log-rank test. The lo-
gistic regression model and Cox proportional regression model
were applied to the overall response and survival analysis,
respectively, to evaluate the potential impact of confounders on the
association, using the forward and backward stepwise method,
with threshold p-values of 0.05 and 0.20 for entry into and removal
from the model, respectively. Age, gender, smoking status, disease
stage, Eastern Cooperative Oncology Group (ECOG) PS, type of EGFR
mutations, and lines of geﬁtinib monotherapy were adjusted for in
the multivariate analysis. All p-values were obtained from two-
sided tests, and signiﬁcance was set at p < 0.05. Statistical ana-
lyses were conducted using STATA software (ver. 13; StataCorp,
College Station, TX, USA).
3. Results
3.1. Patient demographics and geﬁtinib treatment
Fig. 1 shows the study ﬂow. We identiﬁed 52 patients with
advanced NSCLC harboring EGFR mutations for further assess-
ments. The patient demographic information is listed in Table 1.
Most of the patients had a PS of 0e1 (n ¼ 48, 92.3%) and exhibited
adenocarcinoma histology (n ¼ 49, 94.2%). Regarding the type of
EGFR mutation, there were 29 patients with exon 19 tumours, 18
exon 21 tumours, and ﬁve other mutations.
Fig. 1. Flow chart showing the progress of the study.
Fourteen of 28 and 11 of 24 received platinum-based chemotherapy in Group N and P, respectively.
Abbreviations: EGFR-TKI, epidermal growth factor receptor-tyrosine kinase inhibitor; NSCLC, non-small cell lung cancer; IL-6, interleukin 6.
Table 1
Clinicopathological characteristics.
Variable Total no. of Patients (N ¼ 52) Group N Group P
IL-6 negative (N ¼ 28) IL-6 positive (N ¼ 24)
No. % No. %
Age (median; range) 67 (40-81) e 66 (36-85) e
Sex
Male 24 11 39 13 54
Female 28 17 61 11 46
Smoking history
ever 28 13 46 15 63
never 24 15 54 9 38
Stage
postoperative
recurrence
29 17 61 12 50
III 1 0 0 1 4
IV 22 11 39 11 46
Histology
Ad 49 28 100 21 88
Sq 3 0 0 3 13
Type of EGFR mutation
exon 19 29 17 61 12 50
exon 21 18 9 32 9 38
other 5 2 7 3 13
PS
0-1 48 27 96 21 88
2 4 1 4 3 13
Line of geﬁtinib therapy
ﬁrst-line 28 16 57 12 50
second-line 21 10 36 11 46
third-line 3 2 7 1 4
Values are presented as n (%), except for age.
Abbreviations: EGFR, epidermal growth factor receptor; PS, performance status; IL-6, interleukin 6; Ad, adenocarcinoma; Sq, squamous cell carcinoma.
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developed PD following treatment. Of the 52 patients, 25 (48.1%)
were treated with platinum-based chemotherapy before or after
geﬁtinib treatment during their treatment course (Supplemental
Table 1).3.2. Tumour IL-6 expression
The proportion of IL-6-positive cells among the tumour cells of
each patient ranged from 0% to 97.5% (median: 39.6%). As described
above, expressionwas deﬁned to be positive if 50% of 100 tumour
cells stained positively; 24 (46%) and 28 (54%) of the 52 patients
were judged as IL-6-positive (group P) (Fig. 2AeC) and IL-6-
negative (Group N) (Fig. 2DeF), respectively (Fig. 2G). The charac-
teristics of the two groups were somewhat different (Table 1);
Group P included lower proportions of female patients with poor
PS, never-smokers, and non-squamous cell carcinoma, despite noFig. 2. Tumour IL-6 immunostaining.
A-F. Representative microscopic ﬁndings of IL-6 staining (A-C; Group P,  200, D-F; Group
G. Proportions of IL-6-positive cells among the tumour cells of each patient. Red and blue plo
in this ﬁgure legend, the reader is referred to the web version of this article.)statistically signiﬁcant differences.3.3. IL-6 and survival
Among the whole 52 patients, 26 achieved partial response
(50%; 95% conﬁdence interval [CI]: 36-64%). Group P had low
response rate as comparedwith Group N (9 [38%] of 24 v 17 [61%] of
28; p ¼ 0.095). Multivariate analysis also revealed a similar trend
with odds ratio of 0.39 and its 95% CI of 0.13e1.20 (p ¼ 0.098).
The median follow-up time of the patients was 50.9 months. In
the whole 52 patients, 6-month-PFS rate and median PFS were
84.1% and 18.0 months, respectively, whereas OS rate at 1, 2 and 3
years were 88.5%, 72.9%, and 67.8%, respectively. When stratiﬁed by
the IL-6 staining, group P experienced a worse PFS than that of
group N (74.5% vs. 92.4% at 6 months, and median of 13.5 months
vs. not reached, respectively; p ¼ 0.045) (Fig. 3A), and the signiﬁ-
cance was retained in the multivariate analysis (hazard ratio [HR]:N,  200).
ts represent groups P and N, respectively. (For interpretation of the references to colour
Fig. 3. Survival curves.
A. Dotted and solid lines represent the progression-free survival (PFS) curves for
geﬁtinib monotherapy in groups P and N, respectively.
B. Dotted and solid lines represent the PFS curves of the platinum-based chemotherapy
in groups P and N, respectively.
C. Overall survival curves in groups P and N, represented by dotted and solid lines,
respectively; Overall survival was deﬁned as the duration from the initiation of EGFR-
TKI treatment until death.
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Next, we examined the relationship between the tumour IL-6
status and PFS after platinum-based chemotherapy in 25 patients
of the same cohort (Supplemental Table 1). Eleven (44%) and
fourteen (56%) of 25 patients who received the platinum-based
chemotherapy during their treatment course possessed IL-6-
positive and -negative tumours, respectively. The PFS after
platinum-based chemotherapy did not differ between groups P and
N (median; 9.8 vs. 7.0 months, respectively; p ¼ 0.475) (Fig. 3B).
The OS curves according to IL-6 expression status are illustrated
in Fig. 3C. Group P tended to have a worse OS than that of group N
(79.2% vs. 96.4%, 62.5% vs. 82.1%, and 62.5% vs. 73.5%, at 1, 2, and 3
years, respectively), despite the lack of a signiﬁcant difference
(p ¼ 0.342).
3.4. Potential impact of the tumour IL-6 cut-off level on PFS
We performed sensitivity analysis to assess potential variations
and uncertainty regarding the categorisation of IL-6. We chose an
IL-6 score cut-off level of 50% (Supplemental Table 2), which pro-
vided an almost identical HR for PFS as those observed when 20%,
25%, 30%, 35%, 40%, 45%, 55%, 60%, 65%, 70% and 75% cut-off levels
were used. This observation suggests that the use of an IL-6 cut-off
level of 50% in our retrospective study was robust for detecting
subpopulations that would beneﬁt less from geﬁtinib
monotherapy.
3.5. Serum IL-6 level by CLEIA
The serum IL-6 level was assessed in 11 (21%) of 52 patients. The
serum IL-6 level ranged from 0.75 to 23.80 pg/ml (median: 2.90 pg/
ml) (Supplemental Fig. 1A), which rarely correlated with that in the
tumour cells (regression coefﬁcient: 1.69, p¼ 0.294) (Supplemental
Fig. 1B). Additionally, we failed to ﬁnd any signiﬁcant relationship
between the serum IL-6 level and PFS after geﬁtinib monotherapy
(regression coefﬁcient: 0.53, p ¼ 0.055) (Supplemetal Fig. 1C).
3.6. IL-6 expression and sensitivity to geﬁtinib and/or anti-IL-6
antibody in preclinical models
Among 10 EGFR-mutated NSCLC cells, the 11e18 cells harboured
high IL-6 protein expression, whilst PC-9 cells had a low expression
(Fig. 4A). Both of PC-9 and 11e18 had sensitivity to geﬁtinib, but the
latter cells possessed lower sensitivity than PC-9 cells (IC 50;
131 nM vs. 30 nM, respectively) (Fig. 4B and C). Unexpectedly, the
effect of monotherapy with anti-IL-6 antibody was observed
neither in 11e18 nor PC-9 cells in vitro (Fig. 4D and E). In contrast,
the combination of an anti-IL-6 antibody with EGFR-TKIs, geﬁtinib,
erlotinib or rociletinib, showed moderate improvement on the
inhibitory effect of cell proliferation in 11e18 cells (Fig. 4F and
Supplemental Fig. 2A). The combination effect was observed
neither in PC-9 cells nor H1975 cells with low level expression of IL-
6 protein (Supplemental Fig. 2B and 2C). The combination of an
anti-IL-6 antibody with EGFR-TKIs had no additive inhibitory effect
in A549with KRASmutations (Supplemental Fig. 2D). In thismodel,
activation of STAT3, downstream of IL-6 signaling pathway, was
inhibited with anti-IL-6 antibody in 11e18 cells (Fig. 5A). Consistent
with the previous reports [11,12,18], an addition of recombinant IL-
6 activated phosphorylation of STAT3 in PC-9 cells, which was
further accelerated by suppression of EGFR with geﬁtinib (Fig. 5B).
4. Discussion
The present small-scale study demonstrated that the pro-
portions of IL-6-positive cells among tumour cells in the patients
Fig. 4. IL-6 and sensitivity of EGFR-TKI in EGFR-mutant tumour cells.
A. Expression of IL-6 in the supernatant of culture medium.
B. The sensitivity of geﬁtinib in 11e18 cells.
C. The sensitivity of geﬁtinib in PC-9 cells.
D. The sensitivity of anti-IL-6 antibody (blue line) and isotype control IgG (red line) in 11e18 cells.
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Fig. 5. IL-6/STAT3 axis and EGFR-TKI in lung cancer with EGFR mutations.
A. Anti-IL-6 antibody inhibited activation of STAT3 in 11e18 cells.
B. Suppression of EGFR with geﬁtinib accelerated the activation of STAT3 induced by IL-
6 in PC-9 cells.
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EGFR-mutant tumours whose standard therapy was EGFR-TKI,
Group P exhibited both low response rate (38% v 61%; p ¼ 0.095)
and worse PFS (75% v 92% at 6 months; p ¼ 0.045), which was
retained in the multivariate analysis (odds ratio: 0.39, 95% CI:
0.13e1.20; p ¼ 0.098 and HR: 2.39, 95% CI: 1.00e5.68; p ¼ 0.049,
respectively). By contrast, PFS in the platinum-based chemotherapy
did not differ between groups P and N (p¼ 0.475). In the preclinical
model, the NSCLC cell line (11e18) with high IL-6 level showed
relatively low sensitivity to geﬁtinib, but the combination of an
anti-IL-6 antibody with geﬁtinib improved the sensitivity (Fig. 4B, C
and 4F). Furthermore, suppression of EGFR accelerated the activa-
tion of STAT3 induced by IL-6 in PC-9 cells (Fig. 5B).
We found a worse PFS after EGFR-TKI monotherapy in group P
(IL-6-positive tumours) (Fig. 3A), supporting previous preclinical
results of limited growth inhibition by EGFR-TKI alone via protec-
tion from apoptosis in EGFR-mutant cell lines overexpressing IL-6
[11]. These NSCLC cells were dependent on the IL-6 axis for long-
term proliferation/survival [11,12]. By contrast, PFS after
platinum-based chemotherapy did not differ between groups P and
N (Fig. 3B), indicating that the tumour IL-6 expression might clin-
ically affect the effect of EGFR-TKI monotherapy. All of these results
suggest that the inhibition of IL-6 expression is additionally needed
to inhibit tumour growth, particularly in patients harboring EGFR-
mutant tumours with high IL-6 expression. Our clinical and pre-
clinical data may lead to a novel strategy for overcoming resistance
or low sensitivity to EGFR-TKI therapy [19,20]; that is, an IL-6
neutralizing antibody might modify its sensitivity via a decrease
in IL-6-mediated signaling, particularly in IL-6-positive, EGFR-
mutant NSCLC, hopefully leading to further survival improvement.
We were very interested in the potential role of serum IL-6
levels in predicting tumour IL-6 expression levels and outcome.
Unfortunately, the serum IL-6 level did not correlate to either
(Fig. 4B), but an elevated serum IL-6 level was related to disease
severity and outcome in several cancers, including prostate,
ovarian, and pancreatic cancers [21]. This discordance could arise
from the following. First, the serum level is readily affected by any
inﬂammation, in addition to the tumour expression level. Indeed,
IL-6, a pleiotropic cytokine with varied systemic functions, was
originally shown to play a major role in inﬂammatory processes
[20]. Second, in our series, the timing of obtaining serum and
tumour samples was not uniform. Third, our series was restricted
by a small patient population, preventing deﬁnitive results. Thus, a
future, well-designed, large-scaled cohort study is warranted.
This study possesses several limitations.We used a small sample
and a retrospective design; thus, the study is suitable only for hy-
pothesis generation. The clinicopathological characteristics of the
two groups were somewhat different, although the multivariate
analysis we conducted possibly adjusted the confounding factors.
Additional limitations included the low PFS maturity of 55.8% and
the lack of a uniform procedure for patient follow-up. Furthermore,
we did investigate here IL-6 expression level but not TGF-beta level
or relevant signaling expressions. The most critical should be the
lack of validation in the cut-off level of tumour IL-6 expression. We
applied the previous relevant criteria to the current study [15]. Also,
though there is the statistical difference in the PFS between the two
groups treated with geﬁtinib, both groups appeared to have
beneﬁted from the medication. Indeed, even for Group P, the me-
dian PFS is 13.5 months, suggesting a prolonged response to the
therapy. Therefore, we still question whether differentiating IL-6E. The sensitivity of anti-IL-6 antibody (blue line) and isotype control IgG (red line) in PC-9
F. The sensitivity of combination of anti IL-6 antibody and geﬁtinib in 11e18 cells.
Abbreviations: NSCLC, non-small cell lung cancer; IL-6, interleukin 6. (For interpretation of t
this article.)expression at the 50% cut-off point would really ultimately make
a difference in clinical decision making. More work needs to be
done for this issue in the future, using a larger prospective cohort
data. Furthermore, in this study, we could not describe whether
there was any heterogeneity in regards to IL-6 expression between
primary tumours and metastatic sites, because we did not conduct
the biopsies from multiple sites. Regarding the serum IL-6 analysis
by CLEIA, the number of samples was too small to make any claims
and it was not split into the two groups either for analysis. As for
efﬁcacy data of geﬁtinib monotherapy in the 52 patients, overall
response rate, we did have information about PFS but not overall
response rate. All these strongly suggest that our results should be
interpreted with caution, but our results raise critical issues to be
resolved regarding how blocking IL-6 expression levels can
potentially overcome resistance to EGFR-TKI.
In conclusion, patients in group P beneﬁted less from geﬁtinib
therapy, even though this has been a standard therapy, even for
such a population. Our pilot preclinical data also revealed IL-6
expression could have some roles in the sensitivity to geﬁtinib.cells.
he references to colour in this ﬁgure legend, the reader is referred to the web version of
T. Tamura et al. / Biochemical and Biophysical Research Communications 495 (2018) 360e367 367This ﬁnding might support the potential role of IL-6 in active can-
cers and provide a rationale for targeted therapeutic investigations.
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